We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Patients on a shorter dosing regimen in Gilead’s phase 3 remdesivir trial saw clinical improvements similar to those on the 10-day treatment schedule, the drugmaker announced Wednesday, offering hope of a COVID-19 treatment. Read More